徳島大学 / 教育研究者総覧 --- 𠮷田朋広

検索:

徳島大学 ⟩ 病院 ⟩ 診療科 ⟩ 脳·神経·精神科 ⟩ 精神科神経科 ⟩
徳島大学 ⟩ 病院 ⟩ 診療科 ⟩ 脳·神経·精神科 ⟩ 心身症科 ⟩

(researchmapへのインポート用ファイル) [PDF解説] [researchmapへの自動反映について]

研究活動

専門分野

研究テーマ

著書・論文

学術論文(審査論文):

1.	Tomohiko Nakayama, Hidehiro Umehara, Kazuaki Mawatari, Yukiko Tomioka, Tomohiro Yoshida, Hiroya Matsuda, Yui Matsumoto, Rumiko Masuda, Toshiharu Kamishikiryo, Manabu Fuchikami, Masahito Nakataki, Akira Takahashi, Atsushi Tajima, Go Okada and Shusuke Numata : Alterations of Blood Plasma Metabolites, Including Kynurenine and Tryptophan, in Bipolar Disorder, Neuropsychiatric Disease and Treatment, 21, 1067-1073, 2025. (キーワード) kynurenine / metabolome / メタボロミクス (metabolomics) / psychiatric disorder / tryptophan (出版サイトへのリンク) ● Publication site (DOI): 10.2147/NDT.S508021 (文献検索サイトへのリンク) ● Summary page in Scopus @ Elsevier: 2-s2.0-105006852907 (DOI: 10.2147/NDT.S508021, Elsevier: Scopus)
2.	Toshiyuki Shirai, Satoshi Okazaki, Takaki Tanifuji, Shusuke Numata, Tomohiko Nakayama, Tomohiro Yoshida, Kentaro Mouri, Ikuo Otsuka, Noboru Hiroi and Akitoyo Hishimoto : Meta-analyses of epigenetic age acceleration and GrimAge components of schizophrenia or first-episode psychosis., Schizophrenia, 10, 1, 108, 2024. (要約) Schizophrenia is a common chronic psychiatric disorder that causes age-related dysfunction. The life expectancy in patients with schizophrenia is 10 years shorter than that in the general population because of the higher risk of other diseases, such as cardiovascular diseases. Aging studies based on DNA methylation status have received considerable attention. Several epigenetic age accelerations and predicted values of aging-related proteins (GrimAge and GrimAge2 components) have been analyzed in multiple diseases. However, no studies have investigated up to GrimAge and GrimAge2 components between patients with schizophrenia and controls. Therefore, we aimed to conduct multiple regression analyses to investigate the association between schizophrenia and epigenetic age accelerations and GrimAge and GrimAge2 components in seven cohorts. Furthermore, we included patients with first-episode psychosis whose illness duration was often shorter than schizophrenia in our analysis. We integrated these results with meta-analyses, noting the acceleration of GrimAge, GrimAge2, and DunedinPACE, and increase in adrenomedullin, beta-2 microglobulin, cystatin C, and plasminogen activation inhibitor-1 levels, in patients with schizophrenia or first-episode psychosis. These results corroborated the finding that patients with schizophrenia had an increased risk of diabetes, cardiovascular disease, and cognitive dysfunction from a biological perspective. Patients with schizophrenia and first-episode psychosis showed differences in the results when compared with controls. Such analyses may lead to the development of novel therapeutic targets to patients with schizophrenia or relevant diseases from the perspective of aging in the future. (徳島大学機関リポジトリ) ● Metadata: 2013067 (出版サイトへのリンク) ● Publication site (DOI): 10.1038/s41537-024-00531-8 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39548083 ● Search Scopus @ Elsevier (PMID): 39548083 ● Search Scopus @ Elsevier (DOI): 10.1038/s41537-024-00531-8 (徳島大学機関リポジトリ: 2013067, DOI: 10.1038/s41537-024-00531-8, PubMed: 39548083)
3.	Tomoya Takeda, Hidehiro Umehara, Yui Matsumoto, Tomohiro Yoshida, Masahito Nakataki and Shusuke Numata : Schizophrenia and cognitive dysfunction., The Journal of Medical Investigation : JMI, 71, 3.4, 205-209, 2024. (要約) Schizophrenia is a psychiatric disorder with cognitive dysfunction as a core symptom along with positive and negative symptoms. Cognitive dysfunction in schizophrenia can be broadly classified into neurocognitive and social cognitive deficits, with these deficits significantly influencing social functioning. Therapeutic interventions aiming to enhance neurocognition and social cognition have been developed. In this review, we describe the characteristics of cognitive dysfunction in patients with schizophrenia, its relationship to social function, and intervention strategies. J. Med. Invest. 71 : 205-209, August, 2024. (キーワード) Humans / Cognitive Dysfunction / 統合失調症 (schizophrenia) / Schizophrenic Psychology (出版サイトへのリンク) ● Publication site (DOI): 10.2152/jmi.71.205 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39462553 ● Search Scopus @ Elsevier (PMID): 39462553 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.71.205 (DOI: 10.2152/jmi.71.205, PubMed: 39462553)

国内講演発表:

1.	𠮷田朋広, 吉田知哉 (名), 木下倫子, 中瀧理仁, 沼田周助 : 電気けいれん療法施行中にたこつぼ型心筋症を認めたうつ病の症例, 第26回有床総合病院精神精神科フォーラム, 2024年7月.
2.	𠮷田朋広, 中瀧理仁, 沼田周助 : うつ病における抗うつ薬の治療反応性と末梢血のDNAメチル化率の変化との関連, 第54回日本神経精神薬理学会第34回日本臨床精神神経薬理学会合同年会, 2024年5月.
3.	松本唯, 中瀧理仁, 石本良祐, 一宮俊文, 野田尚吾, 前田拓也, 増田太利志, 𠮷田朋広, 青井駿, 山田直輝, 富岡有紀子, 梅原英裕, 土師正太郎, 藤田浩司, 和泉唯信, 沼田周助 : ADの灰白質体積と神経心理検査および髄液アミロイドβの関連性の検討, 【第42回日本認知症学会学術総会, 2023年11月.
4.	松本唯, 中瀧理仁, 石本良祐, 一宮俊文, 野田尚吾, 前田拓也, 増田太利志, 𠮷田朋広, 青井駿, 山田直輝, 富岡有紀子, 梅原英裕, 土師正太郎, 藤田浩司, 和泉唯信, 沼田周助 : 認知症の灰白質体積と神経心理検査および髄液アミロイドβの関連性の検討, 第45回日本生物学的精神医学会年会, 2023年11月.
5.	中山知彦, 梅原英裕, 富岡有紀子, 松本唯, 𠮷田朋広, 上敷領俊晴, 淵上学, 岡田剛, 増田瑠見子, 馬渡一諭, 中瀧理仁, 髙橋章, 岡本泰昌, 沼田周助 : 大うつ病性障害患者における治療前後の血中代謝物濃度の変化, 第45回日本生物学的精神医学会年会, 2023年11月.
6.	中山知彦, 梅原英裕, 富岡有紀子, 松本唯, 𠮷田朋広, 上敷領俊晴, 淵上学, 岡田剛, 増田瑠見子, 馬渡一諭, 中瀧理仁, 髙橋章, 岡本泰昌, 沼田周助 : 双極性障害における血中代謝物の変化, 第33回日本臨床精神神経薬理学会学術集会, 2023年9月.